LYELL

Welcome to the Brand page for “LYELL”, which is offered here for Custom manufacture of pharmaceuticals;the mark consists of the word lyell surrounded by three incomplete circles each of which has an opening at the right.;pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; cells for medical or clinical purposes; pharmaceutical preparations for cell therapy for medical or clinical purposes; pharmaceutical preparations for gene therapy for medical or clinical purposes; kits comprised of cells and pharmaceutical preparations for medical or clinical purposes;medical services; medical services, medical services utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, therapeutic regulation of immune cells; medical services for treatment of cancer;pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; scientific research and development; scientific laboratory services; medical and scientific research; scientific and technological services and biological research and development relating thereto, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, therapeutic regulation of immune cells; scientific and technological services and biological research and development, research and development related to treatment of cancer;.

Its status is currently believed to be active. Its class is unavailable. “LYELL” is believed to be currently owned by “Lyell Immunopharma, Inc.”